OncoHost Welcomes Nobel Prize Winner to Scientific Advisory Board
USA - English
News provided by
Share this article
Share this article
BINYAMINA, Israel, Jan. 11, 2021 /PRNewswire/ OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that renowned biologist and winner of The Nobel Prize in Chemistry, Professor Aaron Ciechanover, has joined the company s scientific advisory board. We are delighted to have Professor Ciechanover, an eminent researcher and physician, join our team. His profound scientific knowledge in protein biology and fundamental discoveries in protein turnover that awarded him the 2004 Nobel Prize in Chemistry will be an invaluable contribution to our research efforts in identifying effective personalized cancer treatments, said Dr. Ofer Sharon, CEO of OncoHost. OncoHost s unique approach to host response analysis and our methods to overcome therapy resistance will be further improved by Prof. Ciechan
Theranica Reports Positive Study Results of Nerivio® for Adolescent Migraine Patients
USA - English
News provided by
Share this article
Share this article
NETANYA, Israel, Dec. 22, 2020 /PRNewswire/ Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that a new peer-reviewed study demonstrates the potential of remote electrical neuromodulation (REN) for the acute treatment of migraine in adolescents. The study used Theranica s Nerivio® therapeutic wearable, currently FDA-cleared for adult patients, and demonstrates that adolescents may also benefit from using the device. Nerivio is currently under review by the FDA for indication expansion to adolescents.
Share this article
Share this article
NETANYA, Israel, Dec. 14, 2020 /PRNewswire/ Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today that a new peer-reviewed systemic review and meta-analysis of randomized controlled trials found that remote electrical neuromodulation (REN) was the only neuromodulation-based acute migraine treatment with sufficient clinical evidence to conclude that it is effective. As non-invasive neuromodulation is an emerging field in the treatment of migraine, an unbiased systemic review was important to understand what may really be benefitting patients, said Prof. Stephen Silberstein, MD, director of the Headache Center at the Jefferson University Hospital in Philadelphia. While the industry should conduct more studies to understand the potential of neuromodulation for migraine treatment, this study certainly helps comparing between the different emerging t